/주식/IRTC
IRTC

IRTC

USD

iRhythm Technologies Inc. Common Stock

$181.100-1.580 (-0.865%)

실시간 가격

Healthcare
의료 기기
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$182.680

고가

$185.040

저가

$177.740

거래량

0.37M

기업 기본 정보

시가총액

5.8B

산업

의료 기기

국가

United States

거래 통계

평균 거래량

0.40M

거래소

NMS

통화

USD

52주 범위

저가 $71현재가 $181.100고가 $212

관련 뉴스

GlobeNewswire

iRhythm Technologies to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today

더 보기
iRhythm Technologies to Participate in Upcoming Investor Conferences
Analyst Upgrades

Canaccord Genuity Maintains Buy on iRhythm Technologies, Raises Price Target to $212

Canaccord Genuity analyst William Plovanic maintains iRhythm Technologies with a Buy and raises the price target from $193 to $212.

더 보기
Canaccord Genuity Maintains Buy on iRhythm Technologies, Raises Price Target to $212
Analyst Upgrades

Citigroup Maintains Buy on iRhythm Technologies, Raises Price Target to $242

Citigroup analyst Joanne Wuensch maintains iRhythm Technologies with a Buy and raises the price target from $205 to $242.

더 보기
Citigroup Maintains Buy on iRhythm Technologies, Raises Price Target to $242
Analyst Upgrades

JP Morgan Maintains Overweight on iRhythm Technologies, Raises Price Target to $240

JP Morgan analyst Allen Gong maintains iRhythm Technologies with a Overweight and raises the price target from $190 to $240.

더 보기
JP Morgan Maintains Overweight on iRhythm Technologies, Raises Price Target to $240
Analyst Upgrades

iRhythm Well-Positioned For 2026 After Upbeat Results And Raised Outlook

iRhythm Technologies beat Q3 estimates with record revenue, raised its 2025 sales outlook, and gained analyst confidence with higher price targets.

더 보기
iRhythm Well-Positioned For 2026 After Upbeat Results And Raised Outlook
Analyst Upgrades

Goldman Sachs Maintains Neutral on iRhythm Technologies, Raises Price Target to $202

Goldman Sachs analyst David Roman maintains iRhythm Technologies with a Neutral and raises the price target from $180 to $202.

Analyst Upgrades

Needham Maintains Buy on iRhythm Technologies, Raises Price Target to $244

Needham analyst David Saxon maintains iRhythm Technologies with a Buy and raises the price target from $193 to $244.